Explore
Validate
Learn
Immunocytochemistry
Chromatin ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Chromatin Immunoprecipitation [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA061646 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA061646, RRID:AB_2684575
- Product name
- Anti-BRD4
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human BRD4, Gene description: bromodomain containing 4, Alternative Gene Names: CAP, HUNK1, HUNKI, MCAP, Validated applications: ChIP, ICC, IHC, Uniprot ID: O60885, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.2 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references miR-1293, a Candidate for miRNA-Based Cancer Therapeutics, Simultaneously Targets BRD4 and the DNA Repair Pathway
miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein
Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival
Takagawa Y, Gen Y, Muramatsu T, Tanimoto K, Inoue J, Harada H, Inazawa J
Molecular Therapy 2020;28(6):1494-1505
Molecular Therapy 2020;28(6):1494-1505
miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein
Tonouchi E, Gen Y, Muramatsu T, Hiramoto H, Tanimoto K, Inoue J, Inazawa J
Scientific Reports 2018;8(1)
Scientific Reports 2018;8(1)
Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival
Lee M, Tayyari F, Pinnaduwage D, Bayani J, Bartlett J, Mulligan A, Bull S, Andrulis I
BMC Cancer 2018;18(1)
BMC Cancer 2018;18(1)
No comments: Submit comment
Supportive validation
- Submitted by
- Atlas Antibodies (provider)
- Main image
- Experimental details
- ChIP-Exo-Seq composite graph for Anti-BRD4 (HPA061646, Lot 000047957) tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh´s Lab at Cornell University.
